Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HitIQ Limited ( (AU:HIQ) ) has shared an announcement.
HITIQ Limited has drawn down an additional $500,000 from its existing R&D Tax Incentive loan facility with No Bull Health Pty Ltd, lifting total borrowings under the arrangement to $1.23 million and providing early access to a further portion of its forecast 2026 R&D tax refund. The short-term funding, to be repaid upon receipt of the 2026 R&D Tax Incentive refund, underscores the company’s reliance on R&D-backed financing to support ongoing product development in concussion management technology, with potential implications for liquidity management and the pace of investment in its growth initiatives.
The most recent analyst rating on (AU:HIQ) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
More about HitIQ Limited
HITIQ Limited (ASX: HIQ) is an Australian concussion management and athlete safety technology company serving sport, clinical and research markets globally. Its core offering, including the PROTEQT solution co-developed with Shock Doctor, uses instrumented smart mouthguards and an analytics platform to deliver real-time head impact data and data-driven safety insights, with adoption already evident in elite Australian sports leagues.
Average Trading Volume: 795,894
Technical Sentiment Signal: Sell
Current Market Cap: A$9.56M
Find detailed analytics on HIQ stock on TipRanks’ Stock Analysis page.